HR Execs on the Move

Yumanity

www.yumanity.com

 
Yumanity Therapeutics is transforming drug discovery for neurodegenerative diseases caused by protein misfolding. Despite the fact that an estimated 50 million people worldwide suffer from diseases affecting the brain and central nervous system, there are no approved disease-modifying therapies or cures. Yumanity is working to identify and develop new, disease-modifying therapies that address several illnesses with critical unmet medical needs, including Alzheimer`s disease, Parkinson`s disease and amyotrophic lateral sclerosis (ALS). The company`s approach concentrates on correcting the cellular pathologies driven by misfolded proteins, the altered biology or phenotypes driving these diseases. Yumanity Therapeutics was founded in December 2014 by Susan ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.yumanity.com
  • 40 Guest Street Suite 4410
    Boston, MA USA 02135
  • Phone: 617.409.5300

Executives

Name Title Contact Details
Ellen Forest
 Chief Human Resources Officer Profile

Similar Companies

DFM

DFM is a Morristown, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Clade Therapeutics

Clade Therapeutics is a well-funded cell therapy company developing novel cell-based medicines for the treatment of cancer and other devastating diseases. The company, located in the heart of Cambridge was recently launched by an exceptional group of academic leaders and successful bioentrepreneurs converging stem cell biology, immunology, regenerative medicine, and gene editing into the next-generation of stem cell-derived medicines.

DotLab

DotLab is shaping the future of women`s healthcare technology by developing the first test for endometriosis, affecting 1 in 10 women worldwide.

EYELA Tokyo Rikakikai Co

EYELA Tokyo Rikakikai Co is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aurion Biotech

With offices in Seattle, Boston and Tokyo, Aurion Biotech is a clinical-stage biotech company, whose mission is to restore vision to millions of patients with its life-changing regenerative therapies. The Company`s first candidate is for the treatment of corneal edema secondary to endothelial dysfunction, and is one of the first clinically validated cell therapies for corneal care. Aurion Biotech is the recipient of the prestigious Prix Galien award for best start-up in biotech. The Company is preparing for clinical trials in the U.S. Privately held, Aurion Biotech is backed by leading investors that include Deerfield, Alcon, Petrichor, Flying L Partners, Falcon Vision / KKR, and Visionary Ventures.